Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-gq7q9 Total loading time: 0 Render date: 2024-07-17T16:32:03.647Z Has data issue: false hasContentIssue false

13 - Prediction and Prevention of Ovarian Hyperstimulation Syndrome

Published online by Cambridge University Press:  31 March 2017

By
Annick Delvigne
Edited by
Botros Rizk  and
Jan Gerris
Botros Rizk
Affiliation:
University of South Alabama
Jan Gerris
Affiliation:
Universiteit Gent, Belgium
Get access
Type
Chapter
Information
Complications and Outcomes of Assisted Reproduction , pp. 124 - 140
Publisher: Cambridge University Press
Print publication year: 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Devroey, P, Polyzos, N P, Blockeel, C. An OHSS-free clinic by segmentation of IVF treatment. Hum Reprod 2011; 26(10):2593–97.CrossRefGoogle ScholarPubMed
Navot, D, Bergh, P A, Laufer, N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992; 58(2):249–61.Google ScholarPubMed
Papanikolaou, E G, Pozzobon, C, Kolibianakis, E M, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006; 85(1):112–20.CrossRefGoogle ScholarPubMed
The Practice Commitee of ASRM. Ovarian hyperstimulation syndrome. Fertil Steril 2008; 90(3):188–92.Google Scholar
Delvigne, A, Demoulin, A, Smitz, J, et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. Hum Reprod 1993; 8:1353–60.Google Scholar
van Dop, P A. Epidemyology, incidence and primary risk for OHSS. Pre-congress courses 6, SIG safety and Quality in ART. ESHRE meeting, 2004.Google Scholar
Lee, T H, Liu, C H, Huang, C C, et al. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 2008; 23(1):160–67.Google ScholarPubMed
Baigent, A, Lashen, H. Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer. Fertil Steril 2011; 95(7):2429.CrossRefGoogle Scholar
Navot, D, Relou, A, Birkenfeld, A, et al. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1988; 159(1):210–15.CrossRefGoogle ScholarPubMed
Aramwit, P, Pruksananonda, K, Kasettratat, N, Jammeechai, K. Risk factors for ovarian hyperstimulation syndrome in Thai patients using gonadotropins for in vitro fertilization. Am J Health Syst Pharm 2008; 65(12):1148–53.CrossRefGoogle ScholarPubMed
Enskog, A, Henriksson, M, Unander, M, Nilsson, L, Brannstrom, M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 1999; 71(5):808–14.CrossRefGoogle ScholarPubMed
Aljawoan, F Y, Hunt, L P, Gordon, U D. Prediction of ovarian hyperstimulation syndrome in coasted patients in an IVF/ICSI program. J Hum Reprod Sci 2012; 5:32–36.CrossRefGoogle Scholar
Koning, A M, Mutsaerts, M A, Kuchenbecker, W K, et al. Complications and outcome of assisted reproduction technologies in overweight and obese women. Hum Reprod 2012; 27(2):457–67.CrossRefGoogle ScholarPubMed
Delvigne, A. Symposium: Update on prediction and management of OHSS. Epidemiology of OHSS. Reprod Biomed Online 2009; 19(1):8–13.CrossRefGoogle ScholarPubMed
Tummon, I, Gavrilova-Jordan, L, Allemand, M C, Session, D. Polycystic ovaries and ovarian hyperstimulation syndrome: a systematic review. Acta Obstet Gynecol Scand 2005; 84(7):611–16.Google ScholarPubMed
The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19(1):41–47.CrossRefGoogle Scholar
Tibi, C, Alvarez, S, Cornet, D, et al. Prédiction des hyperstimulations ovariennes. Contra Fertil Sex 1989; 17(7–8):751–52.Google Scholar
Zhong, Y P, Ying, Y, Wu, H T, et al. Comparison of endocrine profile and in vitro fertilization outcome in patients with PCOS, ovulatory PCO, or normal ovaries. Int J Endocrinol 2012; 2012:492803.CrossRefGoogle ScholarPubMed
Swanton, A, Storey, L, McVeigh, E, Child, T. IVF outcome in women with PCOS, PCO and normal ovarian morphology. Eur J Obstet Gynecol Reprod Biol 2010; 149(1):68–71.CrossRefGoogle ScholarPubMed
Zhao, C, Liu, X, Shi, Z, et al. Role of serum miRNAs in the prediction of ovarian hyperstimulation syndrome in polycystic ovarian syndrome patients. Cell Physiol Biochem 2015; 35(3):1086–94.CrossRefGoogle ScholarPubMed
Nakhuda, G S, Chu, M C, Wang, J G, Sauer, M V, Lobo, R A. Elevated serum müllerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil Steril 2006; 85(5):1541–43.CrossRefGoogle ScholarPubMed
Nardo, L G, Gelbaya, T A, Wilkinson, H, et al. Circulating basal antimüllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril 2009; 92(5):1586–93.CrossRefGoogle ScholarPubMed
Ocal, P, Sahmay, S, Cetin, M, et al. Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet 2011; 28(12):1197–203.CrossRefGoogle ScholarPubMed
Yates, A P, Rustamov, O, Roberts, S A, et al. AMH tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod 2011; 26(9):2353–62.CrossRefGoogle ScholarPubMed
Polyzos, N P, Tournaye, H, Guzman, L, Camus, M, Nelson, S M. Predictors of ovarian response in women treated with corifollitropin alfa for in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril 2013; 100(2):430–37.CrossRefGoogle ScholarPubMed
Broer, S L, Dólleman, M, van Disseldorp, J, et al. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. Fertil Steril 2013; 100(2):420–29.CrossRefGoogle ScholarPubMed
Kwee, J, Elting, M E, Schats, R, McDonnell, J, Lambalk, C B. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod Biol Endocrinol 2007; 15:5–9.Google Scholar
Jayaprakasan, K, Chan, Y, Islam, R, et al. Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. Fertil Steril 2012; 98(3):657–63.CrossRefGoogle Scholar
Rizk, B. Symposium: Update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome. Reprod Biomed Online 2009; 19(1):14–27.CrossRefGoogle ScholarPubMed
Delbaere, A, Smits, G, De Leener, A, Costagliola, S, Vassart, G. Understanding ovarian hyperstimulation syndrome. Endocrine 2005; 26(3):285–90.CrossRefGoogle ScholarPubMed
Daelemans, C, Smits, G, de Maertelaer, V, et al. Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. J Clin Endocrinol Metab 2004; 89(12):6310–15.CrossRefGoogle ScholarPubMed
O’Brien, T J, Harralson, A F, Tran, T, et al. Kinase insert domain receptor/vascular endothelial growth factor receptor 2 (KDR) genetic variation is associated with ovarian hyperstimulation syndrome. Reprod Biol Endocrinol 2014; 9:12–36.Google Scholar
Verit, F F, Cetin, O, Yildirim, O, et al. Neutrophil to lymphocyte ratio is superior to platelet to lymphocyte ratio as an early predictor of moderate/severe ovarian hyperstimulation syndrome. J Obstet Gynaecol 2014; 34(7):639–43.CrossRefGoogle ScholarPubMed
Papanikolaou, E G, Humaidan, P, Polyzos, N P, Tarlatzis, B. Identification of the high-risk patient for ovarian hyperstimulation syndrome. Semin Reprod Med 2010; 28(6):458–62.CrossRefGoogle ScholarPubMed
Delvigne, A, Rozenberg, S. Preventive attitude of physicians to avoid OHSS in IVF patients. Hum Reprod 2001; 16(12):2491–95.CrossRefGoogle ScholarPubMed
Asch, R H, Li, H P, Balmaceda, J P, Weckstein, L N, Stone, S C. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod 1991; 6(10):1395–99.CrossRefGoogle ScholarPubMed
Hendriks, D J, Klinkert, E R, Bancsi, L F, et al. Use of stimulated serum estradiol measurements for the prediction of hyperresponse to ovarian stimulation in in vitro fertilization (IVF). J Assist Reprod Genet 2004; 21(3):65–72.CrossRefGoogle ScholarPubMed
Ho, H Y, Lee, R K, Lin, M H, Hwu, Y M. Estradiol level on day 9 as a predictor of risk for ovarian hyperresponse during controlled ovarian hyperstimulation. J Assist Reprod Genet 2003; 20(6):222–26.Google ScholarPubMed
Jayaprakasan, K, Herbert, M, Moody, E, Stewart, J A, Murdoch, A P. Estimating the risks of ovarian hyperstimulation syndrome (OHSS): implications for egg donation for research. Hum Fertil (Camb) 2007; 10(3):183–87.CrossRefGoogle ScholarPubMed
Steward, R G, Lan, L, Shah, A A, et al. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril 2014; 101(4):967–73.CrossRefGoogle ScholarPubMed
Enskog, A, Nilsson, L, Brännström, M. Peripheral blood concentrations of inhibin B are elevated during gonadotrophin stimulation in patients who later develop ovarian OHSS and inhibin A concentrations are elevated after OHSS onset. Hum Reprod 2000; 15(3):532–38.CrossRefGoogle ScholarPubMed
Ulcova-Gallova, Z, Babcova, K, Micanova, Z, Bibkova, K, Rumpik, D. Hyperstimulation syndrome: the levels of inhibin A and B in sera and follicular fluids. Gynecol Endocrinol 2014; 30(4):298–301.CrossRefGoogle Scholar
Kung, F T, Chang, S Y, Huang, F J, Lan, KC. VEGF, IVF clinical variables and ovarian hyperstimulation syndrome: a prospective study of the preimplantation luteal phase. J Reprod Med 2007; 52(5):365–74.Google ScholarPubMed
Geva, E, Lessing, J B, Lerner-Geva, L, et al. Elevated levels of interleukin-6 in the follicular fluid at the time of oocyte retrieval for in vitro fertilization may predict the development of early-form ovarian hyperstimulation syndrome. Fertil Steril 1997; 68(1):133–37.CrossRefGoogle ScholarPubMed
McElhinney, B, Ardill, J, Caldwell, C, Lloyd, F, McClure, N. Variations in serum vascular endothelial growth factor binding profiles and the development of ovarian hyperstimulation syndrome. Fertil Steril 2002; 78(2):286–90.CrossRefGoogle ScholarPubMed
Pau, E, Alonso-Muriel, I, Gómez, R, et al. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Hum Reprod 2006; 21(6):1453–60.CrossRefGoogle ScholarPubMed
Mocanu, E, Redmond, M L, Hennelly, B, Collins, C, Harrison, R. Odds of ovarian hyperstimulation syndrome (OHSS) – time for reassessment. Hum Fertil (Camb) 2007; 10(3):175–81.CrossRefGoogle ScholarPubMed
Delvigne, A, Dubois, M, Battheu, B, et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. Hum Reprod 1993; 8(9):1361–66.Google ScholarPubMed
Heijnen, E M, Eijkemans, M J, De Klerk, C, et al. A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial. Lancet 2007; 369(9563):743–49.CrossRefGoogle ScholarPubMed
Olivennes, F, Howies, C M, Borini, A, et al. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. Reprod Biomed Online 2011; 22(Suppl 1):S73–82.CrossRefGoogle Scholar
Yovich, J, Stanger, J, Hinchliffe, P. Targeted gonadotrophin stimulation using the PIVET algorithm markedly reduces the risk of OHSS. Reprod Biomed Online 2012; 24(3):281–92.CrossRefGoogle ScholarPubMed
Figen Turkcapar, A, Seckin, B, Onalan, G, Ozdener, T, Batioglu, S. Human menopausal gonadotropin versus recombinant FSH in polycystic ovary syndrome patients undergoing in vitro fertilization. Int J Fertil Steril 2013; 6(4):238–43.Google ScholarPubMed
Devroey, P, Pellicer, A, Nyboe Andersen, A, Arce, J C. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRHantagonist cycle with compulsory single-blastocyst transfer. Fertil Steril 2012; 97(3): 561–71.CrossRefGoogle Scholar
Al-Inany, H G, Youssef, M A, Aboulghar, M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.Cochrane Database Syst Rev 2011; 11(5):CD001750.CrossRefGoogle Scholar
Kolibianakis, E M, Collins, J, Tarlatzis, B C, et al. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006; 12(6):651–71.CrossRefGoogle ScholarPubMed
Pundir, J, Sunkara, S K, El-Toukhy, T, Khalaf, Y. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reprod Biomed Online 2012; 24(1):6–22.CrossRefGoogle ScholarPubMed
Xiao, J, Chen, S, Zhang, C, Chang, S. Effectiveness of GnRH antagonist in the treatment of patients with polycystic ovary syndrome undergoing IVF: a systematic review and meta-analysis. Gynecol Endocrinol 2013; 29(3):187–91.CrossRefGoogle ScholarPubMed
Palomba, S, Falbo, A, La Sala, G B. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. Br J Obstet Gynaecol 2013; 120(3):267–76.CrossRefGoogle ScholarPubMed
Tso, L O, Costello, M F, Albuquerque, L E, Andriolo, R B, Macedo, C R. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2014; 18(11):CD006105.Google Scholar
Shapiro, B S, Daneshmand, S T, Garner, F C, et al. Effects of the ovulatory serum concentration of human chorionic gonadotropin on the incidence of ovarian hyperstimulation syndrome and success rates for in vitro fertilization. Fertil Steril 2005; 84(1):93–98.CrossRefGoogle ScholarPubMed
Kashyap, S, Parker, K, Cedars, M I, Rosenwaks, Z. Ovarian hyperstimulation syndrome prevention strategies: reducing the human chorionic gonadotropin trigger dose. Semin Reprod Med 2010; 28(6):475–85.CrossRefGoogle ScholarPubMed
Tsoumpou, I, Muglu, J, Gelbaya, T A, Nardo, L G. Symposium: Update on prediction and management of OHSS. Optimal dose of HCG for final oocyte maturation in IVF cycles: absence of evidence? Reprod Biomed Online 2009; 19(1):52–58.CrossRefGoogle ScholarPubMed
van der Linden, M, Buckingham, K, Farquhar, C, Kremer, J A, Metwally, M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2011; (10):CD009154.CrossRefGoogle ScholarPubMed
Huang, J Y, Chian, R C, Tan, S L. Ovarian hyperstimulation syndrome prevention strategies: in vitro maturation. Semin Reprod Med 2010; 28(6):519–31.CrossRefGoogle ScholarPubMed
Sher, G, Salem, R, Feinman, M, et al. Eliminating the risk of life-endangering complications following overstimulation with menotropin fertility agents: a report on women undergoing in vitro fertilization and embryo transfer. Obstet Gynecol 1993; 81(6):1009–11.Google ScholarPubMed
Delvigne, A, Rozenberg, S. A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients. Hum Reprod Update 2002; 8(3):291–96.CrossRefGoogle ScholarPubMed
Levinsohn-Tavor, O, Friedler, S, Schachter, M, et al. Coasting – what is the best formula? Hum Reprod 2003; 18(5):937–40.CrossRefGoogle ScholarPubMed
Abdalla, H, Nicopoullos, J D. The effect of duration of coasting and estradiol drop on the outcome of assisted reproduction: 13 years of experience in 1,068 coasted cycles to prevent ovarian hyperstimulation. Fertil Steril 2010; 94(5):1757–63.CrossRefGoogle ScholarPubMed
Aljawoan, F Y, Hunt, L P, Gordon, U D. Prediction of ovarian hyperstimulation syndrome in coasted patients in an IVF/ICSI program. J Hum Reprod Sci 2012; 5(1):32–36.CrossRefGoogle Scholar
D’Angelo, A, Brown, J, Amso, N N. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2011; 15(6):CD002811.Google Scholar
Aboulghar, M. Agonist and antagonist coast. Fertil Steril 2012; 97(3):523–26.CrossRefGoogle ScholarPubMed
Griesinger, G, Diedrich, K, Devroey, P, Kolibianakis, E M. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006; 12(2):159–68.CrossRefGoogle ScholarPubMed
Youssef, M A, Van der Veen, F, Al-Inany, H G, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 2014; 31(10):CD008046.Google Scholar
Kol, S, Humaidan, P, Alsbjerg, B, et al. The updated Cochrane Review 2014 on GnRH agonist trigger: repeating the same errors. Reprod Biomed Online 2015; 30(6):563–65.CrossRefGoogle ScholarPubMed
Griesinger, G, Kolibianakis, E M, Papanikolaou, E G, et al. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen–thawed embryo replacement cycles. Fertil Steril 2007; 88(3):616–21.CrossRefGoogle ScholarPubMed
Iliodromiti, S, Blockeel, C, Tremellen, K P, et al. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Hum Reprod 2013; 28(9):2529–36.CrossRefGoogle ScholarPubMed
Humaidan, P, Polyzos, N P, Alsbjerg, B, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 2013; 28(9):2511–21.CrossRefGoogle ScholarPubMed
Seyhan, A, Ata, B, Polat, M, et al. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 2013; 28(9):2522–28.CrossRefGoogle ScholarPubMed
Papanikolaou, E G, Verpoest, W, Fatemi, H, et al. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertil Steril 2011; 95(3):1174–77.CrossRefGoogle Scholar
Humaidan, P, Engmann, L, Benadiva, C. Luteal phase supplementation after gonadotropin-releasing hormone agonist trigger in fresh embryo transfer: the American versus European approaches. Fertil Steril 2015; 103(4):879–85.CrossRefGoogle ScholarPubMed
Griesinger, G, Schultz, L, Bauer, T, et al. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a “freeze-all” strategy: a prospective multicentric study. Fertil Steril 2011; 95(6):2029–33.CrossRefGoogle Scholar
Fatemi, H M, Popovic-Todorovic, B, Humaidan, P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril 2014; 101(4):1008–11.CrossRefGoogle ScholarPubMed
Jayasena, C N, Comninos, A N, Nijher, G M, et al. Twice-daily subcutaneous injection of kisspeptin-54 does not abolish menstrual cyclicity in healthy female volunteers. J Clin Endocrinol Metab 2013; 98(11):4464–74.CrossRefGoogle Scholar
Martínez, F, Mancini, F, Solé, M, et al. Antagonist rescue of agonist IVF cycle at risk of OHSS: a case series. Gynecol Endocrinol 2014; 30(2):145–48.CrossRefGoogle ScholarPubMed
D’Angelo, A, Amso, N. Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2007; 18(3):CD002806.Google Scholar
Leitao, V M, Moroni, R M, Seko, L M, Nastri, C O, Martins, W P. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2014; 101(3):664–75.CrossRefGoogle ScholarPubMed
Kasum, M, Vrčić, H, Stanić, P, et al. Dopamine agonists in prevention of ovarian hyperstimulation syndrome. Gynecol Endocrinol 2014; 5:1–5.Google Scholar
Kitsou, C, Kosmas, I, Lazaros, L, et al. Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and calcium pathways: a preclinical randomized study. Gynecol Endocrinol 2014; 30(8):587–92.CrossRefGoogle ScholarPubMed
Akman, L, Sahin, G, Erbas, O, et al. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.Gynecol Endocrinol 2015; 20:1–5.Google Scholar
Várnagy, A, Bódis, J, Mánfai, Z, et al. Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome. Fertil Steril 2010; 93(7):2281–84.CrossRefGoogle ScholarPubMed
El-Khayat, W, Elsadek, M. Calcium infusion for the prevention of ovarian hyperstimulation syndrome: a double-blind randomized controlled trial. Fertil Steril 2015; 103(1):101–05.CrossRefGoogle ScholarPubMed
Endo, T, Honnma, H, Hayashi, T, et al. Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Hum Reprod 2002; 17(10):2548–51.CrossRefGoogle ScholarPubMed
Youssef, M A, Al-Inany, H G, Evers, J L, Aboulghar, M. Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2011; 16(2):CD001302.Google Scholar
Egbase, P E, Sharhan, M A, Grudzinskas, J G. Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Hum Reprod 1999; 14(6):1421–25.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×